Probing brain circuit and behavior with protein:protein interaction modulators
Probing brain circuit and behavior with protein:protein interaction modulators
批准号:
10607051
负责人:
Fernanda Laezza
金额:
$82.42万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-02-01 至 2026-11-30
关键词:
Action PotentialsAcuteAffectAnhedoniaBehaviorBehavioralBindingBiologicalBiological AssayBiologyBioluminescenceBrainBrain DiseasesCardiacCellsCentral Nervous System AgentsChemicalsClassificationClinicalCollectionCommunitiesComplementComplexDevelopmentDiseaseDoseDrug DesignDrug KineticsElectrophysiology (science)Excretory functionFluorescenceFoundationsFunctional disorderGeneticGlobus PallidusGoalsIon ChannelKnowledgeLeadLigand BindingLigandsLinkLuciferasesManualsMeasuresMental disordersMetabolicMetabolismMolecularMolecular ProbesMotivationMusNatureNervous SystemNeuronsNeuropharmacologyNucleus AccumbensOutcomeOutputPathway interactionsPermeabilityProcessProtein IsoformsProteinsRegulationResearchRewardsRoleSCN8A geneSliceSolubilitySurface Plasmon ResonanceTherapeuticToxic effectTransgenic MiceValidationVentral Tegmental Areaabsorptionaddictionbehavior testblood-brain barrier permeabilizationcell typeclinical efficacydesigndrug discoveryfibroblast growth factor-14flexibilitygamma-Aminobutyric Acidhedonichigh throughput screeningimprovedin vitro activityin vivoinnovationintermolecular interactionloss of functionluminescencemotivated behaviormutantnanomolarneural circuitneuronal excitabilityneuropsychiatric disordernovelnovel therapeutic interventionoptogeneticspatch clamppre-clinicalprotein protein interactionpsychologicreceptorresponsesmall moleculesmall molecule librariestherapeutic developmenttoolvalidation studiesvoltage
中文摘要
摘要
精神疾病是与脑回路的适应不良可塑性相关的复杂脑障碍,
我们缺乏临床疗效的预测性临床前测量。为了填补这一空白,我们需要使用分子
为开发新型探针提供信息的知识,以询问电路基础的机制
这些疾病的缺陷,并推动先进的治疗设计。离子内蛋白质-蛋白质相互作用(PPI)
通道复合物微调神经元的兴奋性,并正在成为精神疾病的生物学联系。
紊乱它们的高度特异性和灵活的界面使蛋白质-通道相互作用成为探针的理想靶点
发展这样的分子探针将为神经药理学界提供最佳的研究
分析大脑疾病的复杂性并实现更有效的药物设计的工具。
我们已经确定了电压门控Na+(Nav)Nav1.6通道及其辅助调节器之间的PPI
蛋白质,成纤维细胞生长因子14(FGF 14)作为功能相关的调节介质棘的兴奋性
神经元(MSN)在脑桥核(NAc);中皮质边缘回路的中央组成部分,
功能障碍与广泛的神经精神障碍有关。通过
基于生物发光的高通量筛选(HTS)和一轮化学优化,我们已经确定
新的脑可渗透探针1028,其调节FGF 14:Nav1.6通道复合物的形成并增加
Nav1.6频道可用性和MSN射击。当全身给药时,1028增加了
在缺乏动机的情况下,神经元放电并促进享乐状态,这表明该化合物可以
调节中皮层边缘回路中与奖赏相关的行为。在此,我们建议进一步
通过提高其效力和代谢稳定性优化1028用于体内使用,并确定其
在分子(目标1)、细胞(目标2)、电路和行为水平(目标3)发挥作用。这件事的结果
拟议中的研究将产生一流的大脑渗透化学探针,以询问奖励
电路,为治疗前开发一类新的基于PPI的电极导线提供基础,用于广泛的
一系列精神疾病
英文摘要
ABSTRACT
Psychiatric diseases are complex brain disorders associated with maladaptive plasticity of the brain circuit for
which we lack predictive preclinical measures of clinical efficacy. To fill this gap, we need to use molecular
knowledge to inform development of novel probes in order to interrogate the mechanisms that underlie circuit
deficits in these disorders and drive advanced therapeutic design. Protein-protein interactions (PPI) within ion
channel complexes fine-tune neuronal excitability and are emerging as links to the biology of psychiatric
disorders. Their highly specific and flexible interfaces make protein-channel interactions ideal targets for probe
development. Such molecular probes would provide the neuropharmacology community with optimal research
tools to parse out brain disease complexities and enable more effective drug design.
We have identified the PPI between the voltage-gated Na+ (Nav) Nav1.6 channel and its accessory regulator
protein, fibroblast growth factor 14 (FGF14) as a functionally relevant regulator of excitability of medium spiny
neurons (MSN) in the nucleus accumbens (NAc); a central component of the mesocorticolimbic circuit whose
dysfunction has been associated with a wide spectrum of neuropsychiatric disorders. Through a
bioluminescence-based high-throughput screen (HTS) and a round of chemical optimization we have identified
the new brain permeable probe 1028 that modulates FGF14:Nav1.6 channel complex formation and increases
Nav1.6 channel availability and MSN firing. When systemically administrated, 1028 increases accumbal
neuron firing and promotes hedonic states in situations lacking motivation, suggesting the compound can
modulate reward-related behaviors within the mesocorticolimbic circuit. Here, we are proposing to further
optimize 1028 for in vivo use by improving its potency and metabolic stability and determine its mechanism of
action at the molecular (Aim 1), cellular (Aim 2), circuital, and behavioral levels (Aim 3). Outcomes of this
proposed research will generate the first-in-class brain-permeant chemical probes to interrogate the reward
circuit, providing the foundation for pre-therapeutic development of a new class of PPI-based leads for a broad
spectrum of psychiatric disorders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Brain derived extracellular vesicles-mediated neurotoxicity of deltamethrin
-
批准号:10679858
-
项目类别:
-
资助金额:$42.34万
-
财政年份:2023
-
负责人:Fernanda Laezza
-
依托单位:
Neurotrophin-dependent regulation of voltage-gated sodium channels
-
批准号:10443551
-
项目类别:
-
资助金额:$59.18万
-
财政年份:2020
-
负责人:Fernanda Laezza
-
依托单位:
Neurotrophin-dependent regulation of voltage-gated sodium channels
-
批准号:10615846
-
项目类别:
-
资助金额:$59.18万
-
财政年份:2020
-
负责人:Fernanda Laezza
-
依托单位:
Neurotrophin-dependent regulation of voltage-gated sodium channels
-
批准号:10183336
-
项目类别:
-
资助金额:$59.18万
-
财政年份:2020
-
负责人:Fernanda Laezza
-
依托单位:
Discovery of Chemical Probes for Psychiatric Disorders and Addiction
-
批准号:9252858
-
项目类别:
-
资助金额:$51.83万
-
财政年份:2016
-
负责人:Fernanda Laezza
-
依托单位:
Discovery of Chemical Probes for Psychiatric Disorders and Addiction
-
批准号:9353468
-
项目类别:
-
资助金额:$54.89万
-
财政年份:2016
-
负责人:Fernanda Laezza
-
依托单位:
Validation of FGF14 as a New Molecular Target of GSK3
-
批准号:8838257
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2012
-
负责人:Fernanda Laezza
-
依托单位:
Validation of FGF14 as a New Molecular Target of GSK3
-
批准号:9061830
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2012
-
负责人:Fernanda Laezza
-
依托单位:
Validation of FGF14 as a New Molecular Target of GSK3
-
批准号:8660342
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2012
-
负责人:Fernanda Laezza
-
依托单位:
Validation of FGF14 as a New Molecular Target of GSK3
-
批准号:8373279
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2012
-
负责人:Fernanda Laezza
-
依托单位:
Validation of FGF14 as a New Molecular Target of GSK3
-
批准号:8515528
-
项目类别:
-
资助金额:$36.72万
-
财政年份:2012
-
负责人:Fernanda Laezza
-
依托单位:
海外基金